Added to YB: 2025-08-04
Pitch date: 2025-07-31
NVO [neutral]
Novo Nordisk A/S
+9.14%
current return
Author Info
Kontra Investment Xchange is trying to build wealth by investing in good companies and letting those investments compound over many years. Sign up for the newsletter.
Company Info
Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally.
Market Cap
DKK 1.4T
Pitch Price
DKK 294.26
Price Target
N/A
Dividend
3.64%
EV/EBITDA
8.92
P/E
13.70
EV/Sales
4.72
Sector
Pharmaceuticals
Category
turnaround
Novo Nordisk's ($NVO) shock profit warning: Panic selling or a generational buying opportunity?
NVO (earnings update): Profit warning (8-14% vs 13-21% sales growth, 10-16% vs 16-24% EBIT) sparked selloff, now 12.1x 2026 P/E. Fundamentals strong: Wegovy gaining market share (40.3%, +9.6% prescriptions), CVS formulary switch helping. LT opportunity massive - obesity market at just 1% penetration, oligopoly with Lilly. Buy when others panic.
Read full article (4 min)